Biotech stocks have been booming over the last few years. Anyone who has invested will have made some very respectable profits. And it's a bull market that's set to continue for some time yet.
Biotechnology firms are benefiting from demand from ageing populations. But as Dr Daniel Koller explains, there’s more to the biotech boom than that.
AstraZeneca’s interest in a small biotech firm is a reminder of why tiny drug companies are so important, says David Thornton.
Neil Woodford’s new start-up fund will get plenty of hype, says David Thornton. But penny share investors should buy this stock instead.
Investment manager Carl Harald Janson tips three biotech stocks to profit from the full range of opportunities this exciting sector has to offer.
The field of gene therapy struggled at first – to the point where some doubted it altogether. But 2014 saw some outstanding successes, says Tom Bulford.
Science is only just getting to grips with the fact that 90% of our body is made up of bacteria – the microbiome. Bengt Saelensminde investigates.
Stephen O’Hara’s biotech company Optibiotix aims to profit from the ‘human microbiome’. David Thornton explains what that is, and what it means for investors.
We live in a golden age of unprecedented technological change. Smart investors should get in early, says Jim Mellon.
Technological change is everywhere, says Merryn Somerset Webb. Investors who don’t want to be left behind should read Jim Mellon’s new book.
Biotech companies will soon be able to get new drugs to patients much faster. That’s good news for patients and investors, says Matthew Partridge.